Helen Torley - 17 Jan 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: PRESIDENT AND CEO, Director
Signature: /s/ James R. Oehler, Attorney-in-Fact
Issuer symbol: HALO
Transactions as of: 17 Jan 2023
Net transactions value: -$1,539,149
Form type: 4
Filing time: 19 Jan 2023, 16:07:31 UTC
Previous filing: 15 Dec 2022
Next filing: 09 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Options Exercise	$146,600	+10,000	+1.7%	$14.66	597,177	17 Jan 2023	Direct	F1
transaction	HALO	Common Stock	Sale	$448,364	-8,897	-1.5%	$50.40	588,280	17 Jan 2023	Direct	F1, F2
transaction	HALO	Common Stock	Sale	$56,175	-1,103	-0.19%	$50.93	587,177	17 Jan 2023	Direct	F1, F3
transaction	HALO	Common Stock	Options Exercise	$146,600	+10,000	+1.7%	$14.66	597,177	18 Jan 2023	Direct	F1
transaction	HALO	Common Stock	Sale	$510,470	-10,000	-1.7%	$51.05	587,177	18 Jan 2023	Direct	F1, F4
transaction	HALO	Common Stock	Options Exercise	$146,600	+10,000	+1.7%	$14.66	597,177	19 Jan 2023	Direct	F1
transaction	HALO	Common Stock	Sale	$524,140	-10,000	-1.7%	$52.41	587,177	19 Jan 2023	Direct	F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Options Exercise	$146,600	-10,000	-11%	$14.66	80,000	17 Jan 2023	Common Stock	10,000	$14.66	Direct	F1, F6
transaction	HALO	Option to Purchase Common Stock	Options Exercise	$146,600	-10,000	-12%	$14.66	70,000	18 Jan 2023	Common Stock	10,000	$14.66	Direct	F1, F6
transaction	HALO	Option to Purchase Common Stock	Options Exercise	$146,600	-10,000	-14%	$14.66	60,000	19 Jan 2023	Common Stock	10,000	$14.66	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 7, 2022 in accordance with Rule 10b5-1.
F2	Represents a weighted average sales price per share. The shares were sold at prices ranging from $49.89 to $50.85. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3	Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.89 to $50.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4	Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.75 to $51.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5	Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.13 to $52.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6	Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.